Morgan Stanley Adjusts Neurocrine Biosciences Price Target
Morgan Stanley analyst Sean Laaman maintained a 'Neutral' rating on Neurocrine Biosciences while increasing the price target from $185 to $191.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Morgan Stanley analyst Sean Laaman maintained a 'Neutral' rating on Neurocrine Biosciences while increasing the price target from $185 to $191.
DelveInsight released a comprehensive competitive landscape report on GLP-1 receptor agonists and incretin-based therapies, covering 200+ pipeline drugs from 180+ active players. The report highlights approved drugs like MOUNJARO (tirzepatide) and OZEMPIC (semaglutide), with 30+ therapies in late-stage development and 60+ in mid/early stages. Key indications include obesity, type 2 diabetes, and cardiovascular outcomes. Recent developments include positive Phase III results for retatrutide, survodutide, and other dual/triple agonists from major pharmaceutical companies.
Neurocrine Biosciences, Inc. announced that its executives will participate in the 2026 Jefferies Global Healthcare Conference in London on November 17, 2026.
Neurocrine Biosciences released findings from a new survey indicating that adults with tardive dyskinesia report fewer work and school disruptions when treated with INGREZZA.
An analyst firm has raised the 12-month price target for Neurocrine Biosciences, Inc. to $209.27, indicating a potential upside of 44%.
Following the company's third-quarter 2026 financial results, RBC Capital Markets and Deutsche Bank have updated their price targets for Neurocrine Biosciences.